Home > Research & Development > Current Research
Research creativity is the driving force of ATGen
Based on specialized techniques, ATGen research and develop reagents, diagnosis, and pharmaceutical drugs.
In 2009, ATGen started business in diagnosis market from studies on NK cells and immunity. In 2012, NK Vue® Kit was approved by KFDA. NK Vue® Kit is an in-vitro test that measure NK cell activity, which uses our patented material Promoca to stimulate NK cells in whole blood. NK Vue® Kit has been used in general health care screening to clinical research and diagnostics and proved its superiority.
ATGen’s specialized technique, stable-peptide fusion technology, was designed for proteins that are susceptible to external environment or need to be stored for long-term or in room temperature. It was the core technology that led ATGen to expand their field of expertize. In addition, we have large quantities of recombinant proteins, high purity of recombinant proteins, and various DNA library. We also continued to provide high quality monoclonal antibodies through a specialized antigen designing techniques, a suitable choice of immunological method for specific antigen, a high success rate of the cell fusion, and screening techniques world widely.
Our goal is to become a global leader in biotechnology industry. To achieve our goal, we are continually broaden the field of research to pharmaceutical drugs, such as antibody drugs with maintaining the main markets. Based on the specialized antibody production technologies, the expansion of business areas to diagnosis and therapeutic antibody drug industry will become a key factor for ATGen to grow globally.